Dublin, June 17, 2021 (GLOBE NEWSWIRE) — The report has been added to ResearchAndMarkets.com’s offering.
The global viral vectors and plasmid DNA manufacturing market size is expected to reach USD 8.6 billion by 2028
The market is expected to expand at a CAGR of 18.8% from 2021 to 2028. The robust pipeline for gene therapies and viral-vector-based vaccines has primarily driven the market.
Amidst the COVID-19 pandemic, the demand for viral vectors has rapidly increased especially in vaccinology. This led to expanding manufacturing capabilities by operating players to meet the growing demand. The application of these vectors in vaccine development has witnessed significant growth in 2020.
Also, an increase in the number of gene therapy-based discovery programs initiated by biotechnology and pharmaceutical companies is expected to drive the demand for scalable production of gene therapy vectors. Owing to this, several private and public agencies are providing funds to accelerate advancements in the manufacturing processes for viral vectors.
Besides, the implementation of single-use technology can lead to significant savings in capital, operating costs, materials, and labor. The use of this equipment will enhance efficiency and improve flexibility, leading to high yields of the final product. Thus, advancements in single-use technology directly impact revenue growth in this space.
Viral Vectors And Plasmid DNA Manufacturing Market Report Highlights
- The Adeno Associated Virus (AAV) segment accounted for the significant revenue share in 2020. High usage and promising results in gene therapy clinical trials have boosted its adoption.
- Moreover, several biopharma companies are offering their viral vector platform for the development of AAV-based gene therapy products, thereby driving the segment.
- The downstream processing segment dominated the market in terms of revenue share. This can be attributed to the availability of advanced purification products.
- Owing to the rising demand for cost-effective and scalable manufacturing processes, companies are involved in the development of the upstream cell culture processes.
- This is anticipated to result in the notable growth of the upstream processing segment.
- The vaccinology segment dominated the market in terms of revenue share in 2020.
- The SARS-COV-2 pandemic has supplemented the use of vectors in this segment.
- With the active engagement of the research community in the R&D of advanced therapies, research institutes captured the maximum revenue share in the market.
- The initiation of several R&D programs by pharmaceutical and biopharmaceutical companies to combat the COVID-19 crisis would further propel market growth.
- A rapidly growing pipeline of advanced therapy products for various cancer types has led to lucrative revenue generation in the cancer segment.
- North America maintained its dominance in 2020 owing to the high number of entities engaged in offering products and services for viral vector manufacturing in the U.S..
- Furthermore, the remarkable success of viral vector-based Kymriah, Yescarta, and ZOLGENSMA in the U.S. has also contributed to regional dominance.
- In Asia Pacific, the market is projected to witness the fastest growth rate owing to industrialization and clinical transformation of gene therapy in the region.
- Companies continue to make focused attempts to expand their manufacturing facilities as well as service portfolio to maintain their market presence.
Key Topics Covered:
Chapter 1 Executive Summary
Chapter 2 Research Methodology
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Segmentation & Scope
3.2 Market Dynamics
3.2.1 Market drivers analysis
18.104.22.168 Robust pipeline for gene therapies and viral vector vaccines
22.214.171.124 Technological advancements in manufacturing vectors
126.96.36.199 Highly competitive market and various strategies undertaken by market entities
3.2.2 Market restraint analysis
188.8.131.52 Regulatory, scientific, and ethical challenges associated with gene therapy and viral vectors
3.2.3 Market challenge analysis
184.108.40.206 Production capacity challenges
220.127.116.11 Manufacturing challenges pertaining to large scale production of vectors
3.2.4 Market opportunity Analysis
18.104.22.168 Facility expansion for cell and gene therapies
3.3 COVID-19 Impact Analysis
3.4 Viral Vector Production: Stepwise Challenges & Solutions
3.4.1 Host cell production & banking Needs
3.4.2 Viral vector production, Fill & Finish: challenges & solutions
3.4.3 Viral vector production, analytics: challenges & solutions
3.5 Penetration & Growth Prospect Mapping for Vector Type, 2020
3.6 Industry Analysis – Porter’s
3.7 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.8 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2020
3.9 Manufacturer’s Landscape
3.10 Viral Vector Production Capacity Mapping Analysis
3.10.1 North America: capacity & service mapping
3.10.2 Europe: capacity & service mapping
22.214.171.124 Cobra Biologics (Sweden and the U.K.)
126.96.36.199 Biovian (Finland)
188.8.131.52 Oxford Biomedica (U.K.)
184.108.40.206 Lonza Pharma & Biotech (The Netherlands)
220.127.116.11 FinVector Oy (Finland)
18.104.22.168 Fujifilm Diosynth Biotechnologies (Denmark)
22.214.171.124 Fujifilm Diosynth Biotechnologies (U.K.)
126.96.36.199 Catalent Inc. (Belgium)
188.8.131.52 Novasep (Belgium)
184.108.40.206 Exothera (Belgium)
220.127.116.11 Delphi Genetics SA (Belgium)
18.104.22.168 Yposkesi (France)
22.214.171.124 VIVEbiotech (Spain)
126.96.36.199 MolMed SpA (Italy)
188.8.131.52 Anemocyte (Italy)
3.11 List of Companies with Portfolio Comprising Vector-based Therapeutic Candidates
3.12 List of Vector Manufacturers
Chapter 4 Viral Vector Production: Costs
4.1 Cost Models for Viral Vector Production
4.1.1 Campaign model
4.1.2 Day rate model
4.1.3 Hybrid model
4.2 Viral Vector Manufacturing Pricing Analysis
4.2.1 Parameters affecting price
4.2.2 AAV: Pricing analysis
4.2.3 Lentivirus: Pricing analysis
4.2.4 Adenovirus: Pricing analysis
4.2.5 Retrovirus: Pricing analysis
4.2.6 Plasmid: Pricing analysis
4.2.7 Gene Synthesis Cost
4.2.8 Genes/ Gene Fragment Cost Analysis
Chapter 5 Viral Vector Production & Yield Analysis
5.1 Production Yields: Biomarin, Spark Therapeutics & Solid Biosciences
5.2 Various Modes of Vector Production to increase & achieve Target Doses
5.2.1 Adenoviral vectors
5.2.2 Gamma- retroviral (MLV – murineleukemia virus) vectors
5.2.3 Lentiviral vectors
5.2.4 AAV vectors
5.2.5 rAAV vectors
184.108.40.206 rAAV Production: challenges & solutions
5.3 Total vector quantity produced per day and yield volume using different cell culture systems
5.4 Measures undertaken to optimize manufacturing of viral vectors for cell and gene therapy
5.5 Analysis of large- and small-scale production of viral vectors based on batch size
5.5.1 Small-scale/laboratory-scale cell culture systems
5.5.2 Large-scale cell culture systems
5.6 Common Practices for Small-Scale (10-50L) Adenovirus Vector Manufacturing
Chapter 6 Viral Vector Manufacturing: Process Economic Considerations & Challenges
6.1. Technological Advances in Manufacturing
6.1.1. Stable producer cell lines
6.1.2 Transient production
6.1.3 Lentiviral vector production process
220.127.116.11 Developments in LentiVector platform
6.2 CoGs Analysis of the Baseline Process
6.2.1 Raw material
6.2.2 Labor costs
6.2.3 Process costs
6.3 Regulatory Expectations
6.4 Approaches for Viral Vector Supply Gene Therapy
6.4.1 Gene therapy manufacturing facilities: trends & types
6.4.2 Gene therapy road map: key external trends
Chapter 7 Viral Vector Manufacturing Market: Strategic Alliances
7.1 Is The Time Right To Invest In Gene Therapy Sector?
7.2 Strategic Approaches for Market Scale-Up
7.2.1 Partnership models
7.2.3 Minority interest (ownership)
7.2.4 Joint venture
7.3 Collaborations in Viral Vector Manufacturing Market
7.3.1 Breakthrough growth: Lonza, Oxford Biomedica & others
Chapter 8 Vector Type Business Analysis
8.1 Market: Vector Type Movement Analysis
8.4 Adeno-associated Virus (AAV)
8.6 Plasmid DNA
Chapter 9 Workflow Business Analysis
9.1 Market: Workflow Movement Analysis
9.2 Upstream Processing
9.2.1 Market estimates and forecast, 2017 – 2028 (USD Million)
9.2.2 Vector amplification and expansion
9.2.3 Vector recovery/harvesting
9.3 Downstream Processing
9.3.1 Market estimates and forecast, for 2017 – 2028 (USD Million)
9.3.3 Fill finish
Chapter 10 Application Business Analysis
10.1 Market: Application Movement Analysis
10.2 Antisense & RNAi Therapy
10.2.1 Market for antisense, & RNAi therapy, 2017 – 2028 (USD Million)
10.3 Gene Therapy
10.4 Cell Therapy
10.6 Research Applications
Chapter 11 End-use Business Analysis
11.1 Market: End-use Movement Analysis
11.2 Pharmaceutical and Biopharmaceutical Companies
11.3 Research Institutes
Chapter 12 Disease Business Analysis
12.1 Market: Disease Movement Analysis
12.3 Genetic Disorders
12.4 Infectious Diseases
- Merck KGaA
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- Cobra biologics ltd.
- Thermofisher scientific inc.
- Waisman Biomanufacturing
- Genezen laboratories
- Advanced BioScience Laboratories, Inc. (ABL inc.)
- Novasep holding s.a.s.
- Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
- Vigene Biosciences Inc.
- General Electric Company (GE healthcare).
- CEVEC. pharmaceuticals gmbh
- Batavia Biosciences B.v.
- Biovion oy
- Wuxi AppTec Co., Ltd.
- VGXI, Inc.
- Catalent Inc.
- Miltenyi Biotec gmbh
- Sirion biotech gmbh.
- Virovek incorporation
- BioNTech IMFS GmbH
- VIVEbiotech s.l.
- Creative biogene
- Vibalogics GmbH
- Takara bio Inc.
- Cell and Gene Therapy Catapult
- bluebird bio Inc.
- Addgene Inc.
- Aldevron LLC.
- Astellas Pharma, Inc.
- BioMarin Pharmaceutical, Inc.
- RegenxBio, Inc.
For more information about this report visit